Forecast

The analysts' average price target is €4.32 (+229.77%). The median is €4.32 (+229.77%).

Buy	2
Hold	0
Sell	0

News Go to news feed

Insider purchase at OKYO Pharma: CSO Raj Patil increases holdings

Raj Patil, chief scientific officer of OKYO Pharma, bought 3,363 common shares on the NASDAQ at $1.49 each, bringing his holdings to 20,030 shares. OKYO Pharma is preparing to start a global phase‑3 trial in the second half of the year with about 111 patients to evaluate a single dose of urcosimod for neuropathic corneal pain. » More on de.investing.com
OKYO Pharma: CEO Robert J. Dempsey buys 15,000 shares at $1.54

Chief Executive Officer Robert J. Dempsey purchased 15,000 common shares of OKYO Pharma on the open market at $1.54 per share on the NASDAQ. OKYO Pharma is listed on the Nasdaq Capital Market and plans to start a global phase‑3 single‑dose study of urcosimod for neuropathic corneal pain in the second half of the year with about 111 patients. The company is in the clinical development phase for anterior segment eye therapies. » More on de.investing.com
OKYO Pharma: chief development officer Gary S. Jacob buys 3,500 shares

Gary S. Jacob, chief development officer and director of OKYO Pharma, purchased 3,500 common shares at $1.40 each on the Nasdaq, bringing his total holding to 112,420 shares. OKYO Pharma’s common stock is listed on the Nasdaq Capital Market. The biopharmaceutical company plans to start a global, registration‑enabling Phase 3 study of urcosimod for the treatment of neuropathic corneal pain in the second half of the year, likely with around 111 patients and a single‑dose regimen. » More on de.investing.com

Financials

In the last quarter, OKYO PHARMA LTD Aktie had revenue of €0 and net profit of -€5.5M

(EUR)	Mar 2026	YoY
Revenue	0	-
Gross profit	-807.75	-
Net profit	-5.5M	-
EBITDA	-5.53M	-

Fundamentals

Metric	Value
Market capitalization	€51.33M
Number of shares	38.37M
52-week high/low	€2.76 - €1.16
Dividends	No
Beta	0.05
P/E ratio	-6.48
PEG ratio	0.05
P/B ratio	4.70
P/S ratio	0.00

Company profile

OKYO Pharma Limited, ein präklinisches biopharmazeutisches Unternehmen, entwickelt im Vereinigten Königreich Therapeutika für Patienten, die an entzündlichen Augenerkrankungen und Augenschmerzen leiden. Zu seinem führenden Produkt gehört OK-101 zur Behandlung von Erkrankungen des trockenen Auges. Das Unternehmen entwickelt außerdem OK-201, einen präklinischen Kandidaten für ein lipidiertes Peptidanalogon aus Rindernebennierenmark zur Behandlung von neuropathischen Augenschmerzen. OKYO Pharma Limited wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in London, Vereinigtes Königreich.